MersV1, Ncbi, Merge, bibRecord, 001973

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Identifieur interne : 001973 ( Ncbi/Merge ); précédent : 001972; suivant : 001974

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Auteurs : Yufei Wang [République populaire de Chine] ; Wanbo Tai [États-Unis] ; Jie Yang [États-Unis] ; Guangyu Zhao [République populaire de Chine] ; Shihui Sun [République populaire de Chine] ; Chien-Te K. Tseng [États-Unis] ; Shibo Jiang [États-Unis] ; Yusen Zhou [République populaire de Chine] ; Lanying Du [États-Unis] ; Jimin Gao [République populaire de Chine]

Source :

Human vaccines & immunotherapeutics [ 2164-554X ] ; 2017.

RBID : pubmed:28277821

Descripteurs français

KwdFr :
- Animaux, Calendrier vaccinal, Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Domaines protéiques (immunologie), Femelle, Glycoprotéine de spicule des coronavirus (immunologie), Humains, Infections à coronavirus (), Mâle, Souris SCID, Souris de lignée BALB C, Souris transgéniques, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie).
MESH :
- administration et posologie : Vaccins antiviraux, Vaccins synthétiques.
- immunologie : Coronavirus du syndrome respiratoire du Moyen-Orient, Domaines protéiques, Glycoprotéine de spicule des coronavirus, Vaccins antiviraux, Vaccins synthétiques.
- Animaux, Calendrier vaccinal, Femelle, Humains, Infections à coronavirus, Mâle, Souris SCID, Souris de lignée BALB C, Souris transgéniques.

English descriptors

KwdEn :
- Animals, Coronavirus Infections (prevention & control), Female, Humans, Immunization Schedule, Male, Mice, Inbred BALB C, Mice, SCID, Mice, Transgenic, Middle East Respiratory Syndrome Coronavirus (immunology), Protein Domains (immunology), Spike Glycoprotein, Coronavirus (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
MESH :
- chemical , administration & dosage : Vaccines, Synthetic, Viral Vaccines.
- chemical , immunology : Spike Glycoprotein, Coronavirus, Vaccines, Synthetic, Viral Vaccines.
- immunology : Middle East Respiratory Syndrome Coronavirus, Protein Domains.
- prevention & control : Coronavirus Infections.
- Animals, Female, Humans, Immunization Schedule, Male, Mice, Inbred BALB C, Mice, SCID, Mice, Transgenic.

Abstract

Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD) fragment containing residues 377-588 of MERS-coronavirus (MERS-CoV) spike protein is a critical neutralizing domain and an important vaccine target. Nevertheless, its optimal immunogen dosage and immunization interval, key factors for human-used vaccines that induce protective immunity, have never been investigated. In this study, we optimized these criteria using a recombinant MERS-CoV RBD protein fused with Fc (S377-588-Fc) and utilized the optimal immunization schedule to evaluate the protective efficacy of RBD against MERS-CoV infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice. Compared with one dose and 2 doses at 1-, 2-, and 3-week intervals, a regimen of 2 doses of this protein separated by an interval of 4 weeks induced the strongest antibody response and neutralizing antibodies against MERS-CoV infection, and maintained at a high level during the detection period. Notably, RBD protein at the optimal dosage and interval protected hDPP4-Tg mice against lethal MERS-CoV challenge, and the protection was positively correlated with serum neutralizing antibodies. Taken together, the optimal immunogen dosage and immunization interval identified in this study will provide useful guidelines for further development of MERS-CoV RBD-based vaccines for human use.

DOI: 10.1080/21645515.2017.1296994
PubMed: 28277821

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000D55
to stream PubMed, to step Curation: 000D55
to stream PubMed, to step Checkpoint: 000B53

Links to Exploration step

pubmed:28277821

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.</title>
<author><name sortKey="Wang, Yufei" sort="Wang, Yufei" uniqKey="Wang Y" first="Yufei" last="Wang">Yufei Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tai, Wanbo" sort="Tai, Wanbo" uniqKey="Tai W" first="Wanbo" last="Tai">Wanbo Tai</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yang, Jie" sort="Yang, Jie" uniqKey="Yang J" first="Jie" last="Yang">Jie Yang</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
<wicri:noRegion>Beijing </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shihui" sort="Sun, Shihui" uniqKey="Sun S" first="Shihui" last="Sun">Shihui Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
<wicri:noRegion>Beijing </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name>
<affiliation wicri:level="2"><nlm:affiliation>d Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease , University of Texas Medical Branch , Galveston , TX </wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gao, Jimin" sort="Gao, Jimin" uniqKey="Gao J" first="Jimin" last="Gao">Jimin Gao</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28277821</idno>
<idno type="pmid">28277821</idno>
<idno type="doi">10.1080/21645515.2017.1296994</idno>
<idno type="wicri:Area/PubMed/Corpus">000D55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D55</idno>
<idno type="wicri:Area/PubMed/Curation">000D55</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D55</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B53</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B53</idno>
<idno type="wicri:Area/Ncbi/Merge">001973</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.</title>
<author><name sortKey="Wang, Yufei" sort="Wang, Yufei" uniqKey="Wang Y" first="Yufei" last="Wang">Yufei Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tai, Wanbo" sort="Tai, Wanbo" uniqKey="Tai W" first="Wanbo" last="Tai">Wanbo Tai</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yang, Jie" sort="Yang, Jie" uniqKey="Yang J" first="Jie" last="Yang">Jie Yang</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
<wicri:noRegion>Beijing </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shihui" sort="Sun, Shihui" uniqKey="Sun S" first="Shihui" last="Sun">Shihui Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
<wicri:noRegion>Beijing </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name>
<affiliation wicri:level="2"><nlm:affiliation>d Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease , University of Texas Medical Branch , Galveston , TX , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>d Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease , University of Texas Medical Branch , Galveston , TX </wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="2"><nlm:affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY </wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gao, Jimin" sort="Gao, Jimin" uniqKey="Gao J" first="Jimin" last="Gao">Jimin Gao</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang </wicri:regionArea>
<wicri:noRegion>Zhejiang </wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Male</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, SCID</term>
<term>Mice, Transgenic</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Protein Domains (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Calendrier vaccinal</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Domaines protéiques (immunologie)</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Infections à coronavirus ()</term>
<term>Mâle</term>
<term>Souris SCID</term>
<term>Souris de lignée BALB C</term>
<term>Souris transgéniques</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Domaines protéiques</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Protein Domains</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization Schedule</term>
<term>Male</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, SCID</term>
<term>Mice, Transgenic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Calendrier vaccinal</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à coronavirus</term>
<term>Mâle</term>
<term>Souris SCID</term>
<term>Souris de lignée BALB C</term>
<term>Souris transgéniques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD) fragment containing residues 377-588 of MERS-coronavirus (MERS-CoV) spike protein is a critical neutralizing domain and an important vaccine target. Nevertheless, its optimal immunogen dosage and immunization interval, key factors for human-used vaccines that induce protective immunity, have never been investigated. In this study, we optimized these criteria using a recombinant MERS-CoV RBD protein fused with Fc (S377-588-Fc) and utilized the optimal immunization schedule to evaluate the protective efficacy of RBD against MERS-CoV infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice. Compared with one dose and 2 doses at 1-, 2-, and 3-week intervals, a regimen of 2 doses of this protein separated by an interval of 4 weeks induced the strongest antibody response and neutralizing antibodies against MERS-CoV infection, and maintained at a high level during the detection period. Notably, RBD protein at the optimal dosage and interval protected hDPP4-Tg mice against lethal MERS-CoV challenge, and the protection was positively correlated with serum neutralizing antibodies. Taken together, the optimal immunogen dosage and immunization interval identified in this study will provide useful guidelines for further development of MERS-CoV RBD-based vaccines for human use.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28277821</PMID>
<DateCompleted><Year>2018</Year>
<Month>03</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>7</Issue>
<PubDate><Year>2017</Year>
<Month>07</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Human vaccines & immunotherapeutics</Title>
<ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
</Journal>
<ArticleTitle>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.</ArticleTitle>
<Pagination><MedlinePgn>1615-1624</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2017.1296994</ELocationID>
<Abstract><AbstractText>Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD) fragment containing residues 377-588 of MERS-coronavirus (MERS-CoV) spike protein is a critical neutralizing domain and an important vaccine target. Nevertheless, its optimal immunogen dosage and immunization interval, key factors for human-used vaccines that induce protective immunity, have never been investigated. In this study, we optimized these criteria using a recombinant MERS-CoV RBD protein fused with Fc (S377-588-Fc) and utilized the optimal immunization schedule to evaluate the protective efficacy of RBD against MERS-CoV infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice. Compared with one dose and 2 doses at 1-, 2-, and 3-week intervals, a regimen of 2 doses of this protein separated by an interval of 4 weeks induced the strongest antibody response and neutralizing antibodies against MERS-CoV infection, and maintained at a high level during the detection period. Notably, RBD protein at the optimal dosage and interval protected hDPP4-Tg mice against lethal MERS-CoV challenge, and the protection was positively correlated with serum neutralizing antibodies. Taken together, the optimal immunogen dosage and immunization interval identified in this study will provide useful guidelines for further development of MERS-CoV RBD-based vaccines for human use.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yufei</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tai</LastName>
<ForeName>Wanbo</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Guangyu</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>Shihui</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tseng</LastName>
<ForeName>Chien-Te K</ForeName>
<Initials>CK</Initials>
<AffiliationInfo><Affiliation>d Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease , University of Texas Medical Branch , Galveston , TX , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>e Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Basic Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Yusen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Lanying</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute , New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Jimin</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>a School of Medical Laboratory Science , Wenzhou Medical University , Wenzhou , Zhejiang , China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI098775</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI109094</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI128311</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>03</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Hum Vaccin Immunother</MedlineTA>
<NlmUniqueID>101572652</NlmUniqueID>
<ISSNLinking>2164-5515</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">hDPP4-transgenic mice</Keyword>
<Keyword MajorTopicYN="Y">neutralizing antibodies</Keyword>
<Keyword MajorTopicYN="Y">optimal immunization interval</Keyword>
<Keyword MajorTopicYN="Y">optimal immunogen dosage</Keyword>
<Keyword MajorTopicYN="Y">protection</Keyword>
<Keyword MajorTopicYN="Y">receptor-binding domain</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>3</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28277821</ArticleId>
<ArticleId IdType="doi">10.1080/21645515.2017.1296994</ArticleId>
<ArticleId IdType="pmc">PMC5512770</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Infect Dis. 2015 Feb 15;211(4):508-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25170104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Clin Pract. 2010 Mar;64(4):432-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20039974</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 8;33 Suppl 2:B3-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26022564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Nov;19(11):1819-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2013 Sep;17 (9):e668-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23916548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Transl Med. 2012 Jan 05;10:4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22221900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2008 Jun;172(6):1500-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18467709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Apr 17;10(4):e0123969</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25884189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1981 Oct;144(4):376</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7288216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Feb;89(4):1954-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25428871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(1):e53568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23320093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2016 Nov 22;7:13473</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27874853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Oct 2;371(14 ):1360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25271614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Jun 27;368(26):2487-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23718156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2014 Sep 10;16(3):328-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25211075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2014;5:3067</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Immunol Immunother. 2005 May;54(5):453-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15627214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Dec 23;10(12):e0145561</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26701103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1967 Oct 2;202(1):111-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6071998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27795425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2010 Nov 04;7:299</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21047436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2015;11(5):1244-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25874632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Dec;88(23):13769-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25231316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Sep;20(9):1527-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25148113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2010 Jul 2;397(3):580-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20617558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Jun;13(6):761-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24766432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2007 Jun;4(6):e218</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17579511</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Jun;89(11):6121-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25787280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immune Netw. 2015 Apr;15(2):51-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25922593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Apr 12;25(15):2832-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17092615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Oct 17;34(44):5262-5272</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27667332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Dec;87(24):13134-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24067982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2006 Sep 15;353(1):6-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16793110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014 Apr 29;5(3):e01146-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24781747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014 Jul 22;5(4):e01450-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25053787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25114257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Oct 07;90(1):57-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26446606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2016 Jun;48(2):99-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27433380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2016 Dec;499:375-382</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27750111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2013 Jan;12(1):13-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23256736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2013 Aug 26;10:266</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23978242</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region><li>Texas</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Yufei" sort="Wang, Yufei" uniqKey="Wang Y" first="Yufei" last="Wang">Yufei Wang</name>
</noRegion>
<name sortKey="Gao, Jimin" sort="Gao, Jimin" uniqKey="Gao J" first="Jimin" last="Gao">Jimin Gao</name>
<name sortKey="Sun, Shihui" sort="Sun, Shihui" uniqKey="Sun S" first="Shihui" last="Sun">Shihui Sun</name>
<name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name>
<name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Tai, Wanbo" sort="Tai, Wanbo" uniqKey="Tai W" first="Wanbo" last="Tai">Wanbo Tai</name>
</region>
<name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name>
<name sortKey="Yang, Jie" sort="Yang, Jie" uniqKey="Yang J" first="Jie" last="Yang">Jie Yang</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001973 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001973 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:28277821
   |texte=   Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:28277821" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki